Bone stromal cells in pagetic bone and Paget's sarcoma express RANKL and support human osteoclast formation

Journal of Pathology

Volumn 209, Issue 1, 2006, Pages 114-120

  Sun, S G ^a   Lau, Y S ^b   Sabokbar, A ^c   Athanasou, Nick A ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OITA UNIVERSITY   (Japan)

Author keywords

Osteoclast; Paget's disease; Sarcoma

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN;

AGED; ARTICLE; BONE DEVELOPMENT; CELL CONTACT; CELL ISOLATION; CELL STIMULATION; CELL STRUCTURE; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MONOCYTE; OSTEOCLAST; OSTEOSARCOMA; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; STROMA CELL;

AGED; AGED, 80 AND OVER; BIOLOGICAL FACTORS; BONE NEOPLASMS; CARRIER PROTEINS; CELL COMMUNICATION; CELLS, CULTURED; COCULTURE TECHNIQUES; GENE EXPRESSION; GLYCOPROTEINS; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOPROTEGERIN; OSTEOSARCOMA; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, NEOPLASM; STROMAL CELLS;

EID: 33645987648     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.1953     Document Type: Article

References (26)

1. Roodman GD. Paget's disease of bone. J Clin Invest 2005;115:200-201.
2. Reddy SV, Menaa C, Singer FR, Demulder A, Roodman GD. Cell biology of Paget's disease. J Bone Miner Res 1999;14:3-8.
3. Fechner RE, Mills SE. Tumours of the Bones and Joints. AFIP Third Series. Fascicle 8. 1993; 17-19.
4. Blair HC, Athanasou NA. Recent advances in osteoarticular biology and pathological bone resorption. Histol Histopathol 2004;19:189-199.
5. Fujikawa Y, Quinn JMW, Sabokbar A, McGee JO'D, Athanasou NA. The human mononuclear osteoclast precursor circulates in the monocyte fraction. Endocrinology. 1996;139:4058-4060.
6. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 1998;95:3597-3602.
7. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997;89:309-319.
8. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12.
9. Kudo O, Fujikawa Y, Itonaga I, Torisu H, Sabokbar A, Athanasou NA, et al. Pro-inflammatory cytokine (TNFα/IL1-α) induction of human osteoclast formation. J Pathol 2002;198:220-227.
10. Menaa C, Reddy SV, Kurihara N, Maeda H, Anderson D, Cundy T, et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J Clin Invest 2000;105:1833-1838.
11. Neale S, Smith R, Wass J, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25 dihydroxyvitamin D3 and RANKL. Bone 2000;27:409-416.
12. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982;34:285-290.
13. Hall PA, Levison DA, Woods AL, Yu CC, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol 1990;162:285-294.
14. Horton MA, Lewis D, McNulty K, Pringle JA, Chambers TJ. Monoclonal antibodies to osteoclastomas (giant cell bone tumors): definition of osteoclast-specific cellular antigens. Cancer Res 1985;45:5663-5669.
15. Jevon M, Sabokbar A, Fujikawa Y, Hirayama T, Neale SD, Wass J, et al. Gender and age-related differences in osteoclast formation from circulating precursors. J Endocrinol 2002;172:673-681.
16. Kukita A, Chenu C, McManus LM, Mundy GR, Roodman GD. Atypical multinucleated cells form in long-term marrow cultures from patients with Paget's disease. J Clin Invest 1990;85:1280-1286.
17. Hughes AE, Ralston SH, Marken J, Bell C, MacPherson H, Wallace RG, et al. Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis. Nat Genet 2000;24:45-48.
18. Good DA, Busfield F, Fletcher BH, Duffy DL, Kesting JB, Andersen J, et al. Linkage of Paget's disease of bone to a novel region on human chromosome 18q23. Am J Hum Genet 2002;70:517-525.
19. Whyte MP, Obrecht SE, Finnegan PM, Jones JL, Podgornik MN, McAlister WH, et al. Osteoprotegerin deficiency and juvenile Paget's disease. N Engl J Med 2002;18:175-184.
20. Roodman GD, Kurihara N, Ohsaki Y, Kukita T, Hosking D, Demulder A, et al. Interleukin-6: a potential autocrine/paracrine factor in Paget's disease of bone. J Clin Invest 1992;89:46-52.
21. Neale SD, Schulze E, Smith R, Athanasou NA. The influence of serum cytokines and growth factors on osteoclast formation in Paget's disease. Q J Med 2002;95:233-240.
22. Kudo O, Sabokbar A, Athanasou NA. Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism. Bone 2003;32:1-7.
23. Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz: London, UK, 1991; 41-46.
24. Meunier PJ, Coindre JM, Edouard CM, Arlot ME. Bone histomorphometry in Paget's disease. Quantitative and dynamic analysis of pagetic and non-pagetic bone tissue. Arthritis Rheum 1980;23:1095-1103.
25. Kanis JA. Pathophysiology and Treatment of Paget's Disease of Bone. Martin Dunitz: London, UK, 1991; 38-42.
26. Lau YS, Sabokbar A, Gibbons CL, Giele H, Athanasou N. Phenotypic and molecular studies of giant-cell tumors of bone and soft tissue. Hum Pathol 2005;36:945-954.